Physician profile
Crystal E Ingle
NPI 1629434808
$899.77
in general payments reported to CMS, 2019-2025
11 companies · $327 in 2025
The $327 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $30.91 · 2022: $86.93 · 2023: $276 · 2024: $179 · 2025: $327.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $782.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $781.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $214.23 | 2021-2025 | |
| Phathom Pharmaceuticals, INC. | $174.03 | 2024-2025 | Voquezna |
| Aimmune Therapeutics, INC. | $153.40 | 2024-2025 | Zenpep, Vowst |
| Boston Scientific Corporation | $136.29 | 2023 | Watchman Access System |
| Janssen Biotech, INC. | $75.38 | 2022-2025 | Stelara, Tremfya, Simponi Aria |
| Medtronic, INC. | $44.54 | 2024 | Barrx, Gi Genius |
| Smith+Nephew, INC. | $28.54 | 2023 | Collagenase Santyl |
| Verrica Pharmaceuticals INC. | $24.05 | 2025 | Ycanth |
| Nestle Healthcare Nutrition INC. | $19.01 | 2023 | |
| W. L. Gore & Associates, INC. | $16.71 | 2023 | Excluder Conformable Aaa Endoprosthesis With Active Control |
| Kci USA, INC. | $13.59 | 2023 | Prevena, V.A.C. Veraflo, V.A.C.Ulta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Crystal Ingle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.